The company has received approval from the US Food and Drug Administration (USFDA) for the product, a generic version of Pentasa extended release capsules (500 mg), the Mumbai-based drug major said in a statement. As per March 2022 IQVIA Health data, Pentasa had annualised sales of around USD 213 million in the US market.from Healthcare/Biotech-Industry-Economic Times https://ift.tt/7pSgu2X
via IFTTT
0 comments:
Post a Comment